GTx slapped with "surprise" complete response letter for toremifene
04 November 2009
Katie McQue
Please Login to read the full article.
04 November 2009
Katie McQue
katie.mcque@informa.com
The US
FDA has unexpectedly hit GTx with a complete response letter for its oral selective oestrogen receptor modulator, toremifene 80mg, for a new indication for the prevention of bone fractures in men with prostate cancer who are receiving androgen deprivation therapy (ADT) to treat their cancer....
Please Login to read the full article.
RELATED CONTENT
NEWS
- GTx and Ipsen terminate toremifene deal as label expansion foiled again
- Amgen's Prolia gains FDA OK to strengthen bones in breast, prostate cancer
- ODAC backs ApoPharma's iron chelator, but lacks harmony on prostate cancer trials
- GTx raises $47.5 M to advance Ostarine in cancer-wasting and partner Capesaris
ANALYSIS
Other Informa Analysis
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
